| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6072756 | Journal of the American Academy of Dermatology | 2014 | 11 Pages |
Abstract
Brodalumab demonstrated sustained clinical response and an acceptable safety profile through 120 weeks in patients with moderate to severe psoriasis.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Kim MD, PhD, Craig MD, Alan MD, Elizabeth H.Z. PhD, Cassandra E. PhD, Greg MD, Ajay MD, PhD, Paul MD, PhD,